U.S., Oct. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07220577) titled 'Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis' on Oct. 22.
Brief Summary: The main purpose of this Ph2a study is to evaluate the preliminary efficacy, safety and tolerability of GIA632 when administered to adult participants with moderate to severe atopic dermatitis (AD).
Study Start Date: Nov. 18
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: GIA632
Active treatment arm
OTHER: Placebo
Placebo treatment arm
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Pharmaceuticals
Published by HT Digital C...